Kronos Bio
KRON
KRON was delisted on the 20th of June, 2025.
96 hedge funds and large institutions have $121M invested in Kronos Bio in 2022 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 27 increasing their positions, 32 reducing their positions, and 9 closing their positions.
33% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 9
3% more funds holding
Funds holding: 93 → 96 (+3)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1.49% less ownership
Funds ownership: 65.04% → 63.54% (-1.5%)
9% less capital invested
Capital invested by funds: $133M → $121M (-$12.6M)
16% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 32
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$6.95M |
| 2 |
PFMU
Privium Fund Management (UK)
London,
United Kingdom
|
+$970K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$302K |
| 4 |
Two Sigma Advisers
New York
|
+$281K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$277K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$1.97M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.39M |
| 3 |
PA
Perceptive Advisors
New York
|
-$1.2M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$1.13M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.03M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PP
101
PDT Partners
New York
| – | -$37K | -10,041 | Closed |
|
102
Wells Fargo
San Francisco,
California
| – | -$1.79K | -397 | -76% |
|
|
CAL
103
Capital Advisors Ltd
Shaker Heights,
Ohio
| – | +$117 | +26 | New |
|
104
UBS Group
Zurich,
Switzerland
| – | +$153 | +34 | New |
|
KRON Hedge Fund Activity: Q3 2022 in Review
96 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Kronos Bio (KRON) for Q3 2022, worth a combined $121M — down 9.4% from $133M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new KRON positions and 9 closed out — a net gain of 3 holders — while 27 added to existing stakes and 32 trimmed.
The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $6.95M. The largest seller was Citadel Advisors, cutting an estimated $1.97M.
- 96 institutional investors held Kronos Bio (KRON) as of Q3 2022, up from 93 in Q2 2022.
- Funds reported $121M of Kronos Bio stock for Q3 2022, down 9.4% quarter-over-quarter.
- 12 funds opened new Kronos Bio positions in Q3 2022 and 9 closed out, a net change of +3 holders.
- The largest Kronos Bio buyer in Q3 2022 was Baker Bros. Advisors, an estimated $6.95M added.
- The largest Kronos Bio seller in Q3 2022 was Citadel Advisors, an estimated $1.97M sold.
Based on aggregated 13F filings for Q3 2022.